Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

State-of-the-art imaging system helps locate and count myriad connections between brain nerve cells

Researchers at the Stanford University School of Medicine, applying a state-of-the-art imaging system to brain-tissue samples from mice, have been able to quickly and accurately locate and count the myriad connections between nerve cells in unprecedented detail, as well as to capture and catalog those connections' surprising variety.

18 Nov 2010

New technique to identify cancer biomarkers

The University of Liège has presented TARGETOME, the most recent of its spin-offs, which is also the first to spring from its applied geno-proteomics centre, GIGA.

18 Nov 2010

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Merck announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee has advised that the data presented support an indication for GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer and anal intraepithelial neoplasia (AIN) in both males and females 9 through 26 years of age.

18 Nov 2010

Inovio achieves positive results in Phase I PENNVAX-B study for HIV

Inovio Pharmaceuticals, Inc. , a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has achieved high vaccine-induced response rates and strong magnitude of immune responses in its Phase I clinical study of PENNVAX-B, a DNA vaccine for the prevention of HIV infection.

18 Nov 2010

MedImmune to present data on oncology portfolio at two medical congresses in Europe and the U.S.

Today, MedImmune announced that researchers will present data from its oncology portfolio, including new clinical data, at two upcoming medical congresses in Europe and the United States.

17 Nov 2010

USPTO issues patent to Neogenix’s 16C3 monoclonal antibody for colorectal, pancreatic cancer

Neogenix Oncology, Inc. announced today that the U.S. Patent and Trademark Office (USPTO) has issued patent number 7,829,678 B2, with claims relating to 16C3 antibody, the company's monoclonal antibody for colorectal and pancreatic cancer.

17 Nov 2010

Eisai enters strategic drug discovery collaboration with FORMA Therapeutics

Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., and FORMA Therapeutics announced today that the two companies have signed a strategic drug discovery collaboration.

17 Nov 2010

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today presented data from preclinical studies of three investigational messenger RNA (mRNA) antagonists. These antagonists are based on the locked nucleic acid (LNA) technology platform targets licensed from Santaris Pharma A/S.

17 Nov 2010

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.

17 Nov 2010

ALLOZYNE's AZ17 antagonist shows positive data for treatment of autoimmune diseases

ALLOZYNE Inc. announced today positive data from preclinical studies evaluating AZ17 which is a novel bispecific Th17 antagonist that inhibits the differentiation and effector function of human Th17 cells in vivo.

17 Nov 2010

Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

Progenics Pharmaceuticals, Inc. today announced the initiation of a phase 2 clinical trial of subcutaneous methylnaltrexone in Japan by its collaborator, Ono Pharmaceutical Co., Ltd. The drug, designated ONO-3849 in Japan, is being evaluated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness such as cancer.

17 Nov 2010

UCSF, Pfizer announce partnership to accelerate translation of biomedical research

UCSF and Pfizer, Inc. have formed a new partnership to accelerate the translation of biomedical research into effective new medications and therapies for patients.

16 Nov 2010

Study finds IgE antibody levels double with increasing age

In the first such study since the 1970s, researchers observed a highly statistically significant increase of IgE, a type of antibody associated with allergic reactions.

16 Nov 2010

New ELISA protocol for Midkine detection in blood serum

BioGenes GmbH, a supplier of GMP compliant immunoassay and antibody services, has developed and optimized the first ever fully validated ELISA protocol for Midkine detection in blood serum.

16 Nov 2010

Researchers develop new vaccine delivery system for rotavirus infection

Researchers have developed a promising new approach to vaccination for rotavirus, a common cause of severe diarrheal disease that is responsible for approximately 500,000 deaths among children in the developing world every year.

16 Nov 2010

ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting

ViroPharma Incorporated today announced data in four poster presentations and two oral presentations relating to Cinryze (C1 esterase inhibitor [human]) at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), November 11 through 16 in Phoenix, Ariz.

16 Nov 2010

RBC boosting drugs may undermine breast cancer treatment with Herceptin

Red-blood-cell-boosting drugs used to treat anemia may undermine breast cancer treatment with Herceptin, a targeted therapy that blocks the cancer-promoting HER2 protein, researchers from The University of Texas MD Anderson Cancer Center report in the Nov. 16 edition of Cancer Cell.

16 Nov 2010

Spectrum Pharmaceuticals to present ZEVALIN data at ASH Meeting

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced a total of 11 ZEVALIN related data presentations (five oral, six posters) at the 52nd Annual Meeting of the American Society of Hematology (ASH), being held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.

15 Nov 2010

BioWa grants Agensys license to POTELLIGENT Technology

BioWa, Inc. announced today that it has entered into a license agreement with Agensys, Inc., an affiliate of Tokyo based Astellas Pharma Inc., providing Agensys with access to BioWa's POTELLIGENT® Technology platform for the purpose of identifying antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC).

15 Nov 2010

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Santarus, Inc., a specialty biopharmaceutical company, today announced the commercial U.S. launch of CYCLOSET (bromocriptine mesylate) tablets. CYCLOSET is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus both as monotherapy and in combination with other oral antidiabetic agents.

15 Nov 2010

Antibody News and Research

Further Reading

State-of-the-art imaging system helps locate and count myriad connections between brain nerve cells

New technique to identify cancer biomarkers

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Inovio achieves positive results in Phase I PENNVAX-B study for HIV

MedImmune to present data on oncology portfolio at two medical congresses in Europe and the U.S.

USPTO issues patent to Neogenix’s 16C3 monoclonal antibody for colorectal, pancreatic cancer

Eisai enters strategic drug discovery collaboration with FORMA Therapeutics

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

ALLOZYNE's AZ17 antagonist shows positive data for treatment of autoimmune diseases

Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

UCSF, Pfizer announce partnership to accelerate translation of biomedical research

Study finds IgE antibody levels double with increasing age

New ELISA protocol for Midkine detection in blood serum

Researchers develop new vaccine delivery system for rotavirus infection

ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting

RBC boosting drugs may undermine breast cancer treatment with Herceptin

Spectrum Pharmaceuticals to present ZEVALIN data at ASH Meeting

BioWa grants Agensys license to POTELLIGENT Technology

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Monoclonal Antibody Manufacturing Trends eBook eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News